FindTrial
Sign In

comparing effect of 1% low dose aspirin gel and 0.3% flurbiprofen gel on level of gingival sulcular fluid inflammatory marker PGE2 and on clinical signs of inflammation in periodontitis patients as an adjunct to scaling and root planing

COMPARATIVE EVALUATION OF PGE2 LEVELS IN GINGIVAL CREVICULAR FLUID AND CLINICAL EFFICACY OF LOCALLY DELIVERED 1% LOW DOSE ASPIRIN GEL AND 0.3% FLURBIPROFEN GEL AS AN ADJUNCT TO SCALING AND ROOT PLANING IN THE TREATMENT OF PERIODONTITIS. A RANDOMIZED CONTROLLED TRIAL.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046282
Enrollment
36
Registered
2022-10-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K053- Chronic periodontitis

Interventions

Intervention1: 0.3% flurbiprofen gel: patients in intervention group 3 will be subjected to scaling and root planing followed by 0.3% flurbiprofen gel placement on first visit(baseline) only.This will

Sponsors

SHILPA MATHEW
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged between 20-50 years from both genders. 2.No history of systemic disease 3.Patients with Probing pocket depth 4-6mm. 4.Willingness to comply with the study protocol.

Exclusion criteria

Exclusion criteria: 1.Patients who are undergoing long term non steroidal anti inflammatory drug therapy. 2.Previous history of periodontal therapy within 6 months. 3.Patients on immunotherapy and hormonal therapy. 4.Patients who have received antibiotic therapy in previous 3 months. 5.Patients who are using any form of chemical plaque control agents. 6.Pregnancy or lactating women. 7.Known hypersensitivity to aspirin, flurbiprofen or any NSAIDS. 8.History of Smoking.

Design outcomes

Primary

MeasureTime frame
resolution of clinical signs of inflammation which include reduction in bleeding on probing ,probing pocket depth and reduction in gcf inflammatory marker(PGE2) and gain in clinical attachment levelTimepoint: 30 days—

Secondary

MeasureTime frame
reduction in plaque formationTimepoint: 30 days—

Countries

India

Contacts

Public ContactDr Vijaya Kumar k

yenepoya university

alphonsmariya@gmail.com9108846614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026